AstraZeneca gets two positive EU regulatory opinions for Klygefa
AstraZeneca said the EU Committee for Medicinal Products for Human Use issued positive opinions for Klygefa (gefurulimab) in adults with AChR—positive gMG as an add-on treatment, and noted that approval would make it the first dual-binding nanobody C5 inhibitor available in Europe.